Exploring the Key Role of Nanotechnology on Intratumoral Microbiome Modulation for Cancer Immunotherapy

Abstract

The intratumoral microbiome has emerged as a critical component of the tumor microenvironment (TME), playing a significant role in tumorigenesis, pathological classification, metastasis, and prognosis. The nutrient-rich, hypoxic, acidic, and immunosuppressive nature of the TME facilitates the establishment of diverse intratumoral microbiome communities. In turn, the intratumoral microbiome further contributes to the formation of cold TME through mechanisms such as genetic and epigenetic alterations, pro-inflammatory responses, immune modulation, tumor metastasis, and enhanced drug resistance. Targeting and eliminating the intratumoral microbiome using nanotechnology presents a unique therapeutic strategy for overcoming chemotherapy resistance and improving the immunosuppressive TME. This review summarizes the microbial characteristics of various tumors and microbiome-mediated oncogenic mechanisms, with particular emphasis on recent advancements in nanotechnology aimed at eliminating the intratumoral microbiome and reprogramming the cold TME, thereby enhancing the efficacy of tumor immunotherapy. Our aim is to provide valuable insights to strengthen the effectiveness of tumor immunotherapy.

Keywords

intratumoral microbiome / nanotechnology / tumor immunotherapy / tumor microenvironment

References

[1] S. Peng, F. Xiao, M. Chen, and H. Gao, “Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy,” Advanced Science9, no. 1 (January 2022): e2103836.

[2] C. Martel, de, J. Ferlay, S. Franceschi, et al., “Global Burden of Cancers Attributable to Infections in 2008: A Review and Synthetic Analysis,” Lancet Oncology13, no. 6 (June 2012): 607–615.

[3] M. Shaheen, C. Allen, J. A. Nickoloff, and R. Hromas, “Synthetic Lethality: Exploiting the Addiction of Cancer to DNA Repair,” Blood117, no. 23 (June 2011): 6074–6082.

[4] A. Lewandowska, M. Rudzki, S. Rudzki, T. Lewandowski, and B. Laskowska, “Environmental Risk Factors for Cancer—Review Paper,” Annals of Agricultural and Environmental Medicine26, no. 1 (March 2019): 1–7.

[5] D. C. Whiteman and L. F. Wilson, “The Fractions of Cancer Attributable to Modifiable Factors: A Global Review,” Cancer Epidemiology44 (October 2016): 203–221.

[6] Y. F. Xie, F. Xie, X. X. Zhou, et al., “Microbiota in Tumors: From Understanding to Application,” Advancement of Science9, no. 21 (July 2022): e2200470.

[7] L. Galluzzi, J. M. Bravo-San Pedro, S. Demaria, S. C. Formenti, and G. Kroemer, “Activating Autophagy to Potentiate Immunogenic Chemotherapy and Radiation Therapy,” Nature Reviews Clinical Oncology14, no. 4 (April 2017): 247–258.

[8] Z. Lin, F. Meng, Y. Ma, et al., “In Situ Immunomodulation of Tumors With Biosynthetic Bacteria Promote Anti-Tumor Immunity,” Bioactive Materials32 (February 2024): 12–27.

[9] X. Duan, C. Chan, and W. Lin, “Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy,” Angewandte Chemie International Edition58, no. 3 (January 2019): 670–680.

[10] Z. Zhang, Y. Zhou, S. Zhao, L. Ding, B. Chen, and Y. Chen, “Nanomedicine-Enabled/Augmented Cell Pyroptosis for Efficient Tumor Nanotherapy,” Advancement of Science9, no. 35 (December 2022): e2203583.

[11] E. F. McCarthy, “The Toxins of William B. Coley and the Treatment of Bone and Soft-Tissue Sarcomas,” Iowa Orthopaedic Journal26 (2006): 154–158.

[12] G. D. Sepich-Poore, L. Zitvogel, R. Straussman, J. Hasty, J. A. Wargo, and R. Knight, “The Microbiome and Human Cancer,” Science (New York, NY)371, no. 6536 (March 2021): eabc4552.

[13] W. J. B. K. W. Busch. Aus der Sitzung der medicinischen Section vom 13 November 1867. 1868; 5(5): 137.

[14] C. Huttenhower, D. Gevers, R. Knight, et al., “Structure, Function and Diversity of the Healthy Human Microbiome,” Nature486, no. 7402 (2012): 207–214.

[15] W. S. Garrett, “Cancer and the Microbiota,” Science348, no. 6230 (April 2015): 80–86.

[16] D. Nejman, I. Livyatan, G. Fuks, et al., “The Human Tumor Microbiome Is Composed of Tumor Type-Specific Intracellular Bacteria,” Science368, no. 6494 (May 2020): 973–980.

[17] M. M. Azevedo, C. Pina-Vaz, and F. Baltazar, “Microbes and Cancer: Friends or Faux?,” International Journal of Molecular Sciences21, no. 9 (April 2020): 3115.

[18] A. Wong-Rolle, H. K. Wei, C. Zhao, and C. Jin, “Unexpected Guests in the Tumor Microenvironment: Microbiome in Cancer,” Protein & Cell12, no. 5 (May 2021): 426–435.

[19] A. B. Dohlman, J. Klug, M. Mesko, et al., “A Pan-Cancer Mycobiome Analysis Reveals Fungal Involvement in Gastrointestinal and Lung Tumors,” Cell185, no. 20 (September 2022): 3807–3822.

[20] M. Li, H. Zhou, C. Yang, et al., “Bacterial Outer Membrane Vesicles as a Platform for Biomedical Applications: An Update,” Journal of Controlled Release323 (July 2020): 253–268.

[21] Y. Fu, J. Li, W. Cai, et al., “The Emerging Tumor Microbe Microenvironment: From Delineation to Multidisciplinary Approach-Based Interventions,” Acta Pharmaceutica Sinica B14, no. 4 (April 2024): 1560–1591.

[22] L. Chen, R. Zhao, J. Shen, et al., “Antibacterial Fusobacterium nucleatum-Mimicking Nanomedicine to Selectively Eliminate Tumor-Colonized Bacteria and Enhance Immunotherapy Against Colorectal Cancer,” Advanced Materials (Deerfield Beach, Fla)35, no. 45 (November 2023): e2306281.

[23] C. Gao, X. Wang, B. Yang, et al., “Synergistic Target of Intratumoral Microbiome and Tumor by Metronidazole–Fluorouridine Nanoparticles,” ACS Nano17, no. 8 (April 2023): 7335–7351.

[24] S. Geng, P. Guo, X. Li, et al., “Biomimetic Nanovehicle-Enabled Targeted Depletion of Intratumoral Fusobacterium nucleatum Synergizes With PD-L1 Blockade Against Breast Cancer,” ACS Nano18, no. 12 (March 2024): 8971–8987.

[25] M. Wang, F. Yu, and P. Li, “Intratumor Microbiota in Cancer Pathogenesis and Immunity: From Mechanisms of Action to Therapeutic Opportunities,” Frontiers in Immunology14 (October 2023): 1269054.

[26] I. Messaritakis, K. Vogiatzoglou, K. Tsantaki, et al., “The Prognostic Value of the Detection of Microbial Translocation in the Blood of Colorectal Cancer Patients,” Cancers12, no. 4 (April 2020): 1058.

[27] Z. Zhang, H. Tang, P. Chen, H. Xie, and Y. Tao, “Demystifying the Manipulation of Host Immunity, Metabolism, and Extraintestinal Tumors by the Gut Microbiome,” Signal Transduction and Targeted Therapy4, no. 1 (2019): 41.

[28] S. R. Gill, M. Pop, R. T. Deboy, et al., “Metagenomic Analysis of the Human Distal Gut Microbiome,” Science312, no. 5778 (June 2006): 1355–1359.

[29] C. C. Wong and J. Yu, “Gut Microbiota in Colorectal Cancer Development and Therapy,” Nature Reviews Clinical Oncology20, no. 7 (July 2023): 429–452.

[30] Y. Cheng, Z. Ling, and L. Li, “The Intestinal Microbiota and Colorectal Cancer,” Frontiers in Immunology11 (2020): 615056.

[31] P. Louis, G. L. Hold, and H. J. Flint, “The Gut Microbiota, Bacterial Metabolites and Colorectal Cancer,” Nature Reviews Microbiology12, no. 10 (October 2014): 661–672.

[32] A. E. V. Quaglio, T. G. Grillo, E. C. S. D. Oliveira, L. C. D. Stasi, and L. Y. Sassaki, “Gut Microbiota, Inflammatory Bowel Disease and Colorectal Cancer,” World Journal of Gastroenterology28, no. 30 (August 2022): 4053–4060.

[33] S. Appunni, M. Rubens, V. Ramamoorthy, et al., “Emerging Evidence on the Effects of Dietary Factors on the Gut Microbiome in Colorectal Cancer,” Frontiers in Nutrition8 (2021): 718389.

[34] C. M. Dejea, P. Fathi, J. M. Craig, et al., “Patients With Familial Adenomatous Polyposis Harbor Colonic Biofilms Containing Tumorigenic Bacteria,” Science (New York, NY)359, no. 6375 (February 2018): 592–597.

[35] R. Qu, Y. Zhang, Y. Ma, et al., “Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer,” Advancement of Science10, no. 23 (August 2023): e2205563.

[36] M. Jin, F. Shang, J. Wu, et al., “Tumor-Associated Microbiota in Proximal and Distal Colorectal Cancer and Their Relationships With Clinical Outcomes,” Frontiers in Microbiology12 (2021): 727937.

[37] K. Mima, R. Nishihara, Z. R. Qian, et al., “Fusobacterium nucleatum in Colorectal Carcinoma Tissue and Patient Prognosis,” Gut65, no. 12 (December 2016): 1973–1980.

[38] F. H. Khan, B. A. Bhat, B. A. Sheikh, et al., “Microbiome Dysbiosis and Epigenetic Modulations in Lung Cancer: From Pathogenesis to Therapy,” Seminars in Cancer Biology86, no. pt. 3 (November 2022): 732–742.

[39] M. Song, A. T. Chan, and J. Sun, “Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer,” Gastroenterology158, no. 2 (January 2020): 322–340.

[40] H. M. Chen, Y. N. Yu, J. L. Wang, et al., “Decreased Dietary Fiber Intake and Structural Alteration of Gut Microbiota in Patients With Advanced Colorectal Adenoma,” American Journal of Clinical Nutrition97, no. 5 (May 2013): 1044–1052.

[41] O. A. Stewart, F. Wu, and Y. Chen, “The Role of Gastric Microbiota in Gastric Cancer,” Gut Microbes11, no. 5 (September 2020): 1220–1230.

[42] Z. Liu, D. Zhang, and S. Chen, “Unveiling the Gastric Microbiota: Implications for Gastric Carcinogenesis, Immune Responses, and Clinical Prospects,” Journal of Experimental & Clinical Cancer Research43, no. 1 (April 2024): 118.

[43] E. Bessède and F. Mégraud, “Microbiota and Gastric Cancer,” Seminars in Cancer Biology86, no. pt. 3 (November 2022): 11–17.

[44] M. Wang, G. Yang, Y. Tian, Q. Zhang, Z. Liu, and Y. Xin, “The Role of the Gut Microbiota in Gastric Cancer: The Immunoregulation and Immunotherapy,” Frontiers in Immunology14 (2023): 1183331.

[45] J. Y. Park, H. Seo, C. S. Kang, et al., “Dysbiotic Change in Gastric Microbiome and Its Functional Implication in Gastric Carcinogenesis,” Scientific Reports12, no. 1 (March 2022): 4285.

[46] F. Aviles-Jimenez, F. Vazquez-Jimenez, R. Medrano-Guzman, A. Mantilla, and J. Torres, “Stomach Microbiota Composition Varies Between Patients With Non-Atrophic Gastritis and Patients With Intestinal Type of Gastric Cancer,” Scientific Reports4 (February 2014): 4202.

[47] Y. Cao, H. Xia, X. Tan, et al., “Intratumoural Microbiota: A New Frontier in Cancer Development and Therapy,” Signal Transduction and Targeted Therapy9, no. 1 (2024): 15.

[48] L. Wang, J. Zhou, Y. Xin, et al., “Bacterial Overgrowth and Diversification of Microbiota in Gastric Cancer,” European Journal of Gastroenterology & Hepatology28, no. 3 (March 2016): 261–266.

[49] D. Shao, E. Vogtmann, A. Liu, et al., “Microbial Characterization of Esophageal Squamous Cell Carcinoma and Gastric Cardia Adenocarcinoma From a High-Risk Region of China,” Cancer125, no. 22 (November 2019): 3993–4002.

[50] D. Dai, Y. Yang, J. Yu, et al., “Interactions Between Gastric Microbiota and Metabolites in Gastric Cancer,” Cell Death & Disease12, no. 12 (November 2021): 1104.

[51] M. Z. Qiu, C. Y. He, S. X. Lu, et al., “Prospective Observation: Clinical Utility of Plasma Epstein-Barr Virus DNA Load in EBV-Associated Gastric Carcinoma Patients,” International Journal of Cancer146, no. 1 (January 2020): 272–280.

[52] O. Liao, G. Ye, Q. Du, and J. Ye, “Gastric Microbiota in Gastric Cancer and Precancerous Stages: Mechanisms of Carcinogenesis and Clinical Value,” Helicobacter28, no. 3 (June 2023): e12964.

[53] F. Gao, B. Yu, B. Rao, et al., “The Effect of the Intratumoral Microbiome on Tumor Occurrence, Progression, Prognosis and Treatment,” Frontiers in Immunology13 (2022): 1051987.

[54] G. Yu, M. H. Gail, D. Consonni, et al., “Characterizing Human Lung Tissue Microbiota and Its Relationship to Epidemiological and Clinical Features,” Genome Biology17, no. 1 (July 2016): 163.

[55] S. H. Lee, J. Y. Sung, D. Yong, et al., “Characterization of Microbiome in Bronchoalveolar Lavage Fluid of Patients With Lung Cancer Comparing With Benign Mass Like Lesions,” Lung Cancer102 (December 2016): 89–95.

[56] K. L. Greathouse, J. R. White, A. J. Vargas, et al., “Interaction Between the Microbiome and TP53 in Human Lung Cancer,” Genome Biology19, no. 1 (August 2018): 123.

[57] S. Gomes, B. Cavadas, J. C. Ferreira, et al., “Profiling of Lung Microbiota Discloses Differences in Adenocarcinoma and Squamous Cell Carcinoma,” Scientific Reports9, no. 1 (September 2019): 12838.

[58] P. L. Apopa, L. Alley, R. B. Penney, et al., “PARP1 Is Up-Regulated in Non-Small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin,” Frontiers in Microbiology9 (2018): 1757.

[59] Y. Ma, H. Chen, H. Li, et al., “Intratumor Microbiome-Derived Butyrate Promotes Lung Cancer Metastasis,” Cell Reports Medicine5, no. 4 (April 2024): 101488.

[60] X. Zhou, L. You, Z. Xin, H. Su, J. Zhou, and Y. Ma, “Leveraging Circulating Microbiome Signatures to Predict Tumor Immune Microenvironment and Prognosis of Patients With Non-Small Cell Lung Cancer,” Journal of Translational Medicine21, no. 1 (November 2023): 800.

[61] Z. Mei and D. Li, “The Role of Probiotics in Vaginal Health,” Frontiers in Cellular and Infection Microbiology12 (2022): 963868.

[62] Y. Liang, M. Chen, L. Qin, B. Wan, and H. Wang, “A Meta-Analysis of the Relationship Between Vaginal Microecology, Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia,” Infectious Agents and Cancer14 (2019): 29.

[63] N. Muñoz, F. X. Bosch, X. Castellsagué, et al., “Against Which Human Papillomavirus Types Shall We Vaccinate and Screen? The International Perspective,” International Journal of Cancer111, no. 2 (August 2004): 278–285.

[64] B. Santella, M. T. Schettino, G. Franci, et al., “Microbiota and HPV: The Role of Viral Infection on Vaginal Microbiota,” Journal of Medical Virology94, no. 9 (September 2022): 4478–4484.

[65] S. Xia, S. Li, and H. Li, “HPV-Infection Status and Urinary Incontinence: A Population-Based Analysis of the NHANES 2005–2016,” World Journal of Urology41, no. 6 (June 2023): 1597–1603.

[66] N. Shulzhenko, H. Lyng, G. F. Sanson, and A. Morgun, “Ménage à trois: An Evolutionary Interplay Between Human Papillomavirus, a Tumor, and a Woman,” Trends in Microbiology22, no. 6 (June 2014): 345–353.

[67] E. Gillet, J. F. Meys, H. Verstraelen, et al., “Bacterial Vaginosis Is Associated With Uterine Cervical Human Papillomavirus Infection: A Meta-Analysis,” BMC Infectious Diseases11 (January 2011): 10.

[68] D. H. Watts, M. Fazarri, H. Minkoff, et al., “Effects of Bacterial Vaginosis and Other Genital Infections on the Natural History of Human Papillomavirus Infection in HIV-1-Infected and High-Risk HIV-1-Uninfected Women,” Journal of Infectious Diseases191, no. 7 (April 2005): 1129–1139.

[69] Z. Fan, D. Han, X. Fan, Y. Zeng, and L. Zhao, “Analysis of the Correlation Between Cervical HPV Infection, Cervical Lesions and Vaginal Microecology,” Frontiers in Cellular and Infection Microbiology14 (2024): 1405789.

[70] C. M. Chang and H. Y. P. Lam, “Intratumoral Microbiota: Unraveling Their Oncogenic Impact on Cancer Progression With Focus on Breast Cancer Therapeutic Outcomes,” Anticancer Research44, no. 6 (June 2024): 2271–2285.

[71] D. H. Kim and Y. H. Jin, “Intestinal Bacterial β-Glucuronidase Activity of Patients With Colon Cancer,” Archives of Pharmacal Research24, no. 6 (December 2001): 564–567.

[72] M. Barrett, C. K. Hand, F. Shanahan, T. Murphy, and P. W. O'Toole, “Mutagenesis by Microbe: The Role of the Microbiota in Shaping the Cancer Genome,” Trends in Cancer6, no. 4 (April 2020): 277–287.

[73] R. N. Jinadasa, S. E. Bloom, R. S. Weiss, and G. E. Duhamel, “Cytolethal Distending Toxin: A Conserved Bacterial Genotoxin That Blocks Cell Cycle Progression, Leading to Apoptosis of a Broad Range of Mammalian Cell Lineages,” Microbiology (Reading, England)157, no. pt. 7 (July 2011): 1851–1875.

[74] M. R. Wilson, Y. Jiang, P. W. Villalta, et al., “The Human Gut Bacterial Genotoxin Colibactin Alkylates DNA,” Science (New York, NY)363, no. 6428 (February 2019): eaar7785.

[75] A. Boleij, E. M. Hechenbleikner, A. C. Goodwin, et al., “The Bacteroides fragilis Toxin Gene Is Prevalent in the Colon Mucosa of Colorectal Cancer Patients,” Clinical Infectious Diseases60, no. 2 (January 2015): 208–215.

[76] O. D. Maddocks, K. M. Scanlon, and M. S. Donnenberg, “An Escherichia coli Effector Protein Promotes Host Mutation via Depletion of DNA Mismatch Repair Proteins,” mBio4, no. 3 (June 2013): e00152-13.

[77] J. J. Kim, H. Tao, E. Carloni, W. K. Leung, D. Y. Graham, and A. R. Sepulveda, “Helicobacter pylori Impairs DNA Mismatch Repair in Gastric Epithelial Cells,” Gastroenterology123, no. 2 (August 2002): 542–553.

[78] Y. Suh, I. Amelio, T. Guerrero Urbano, and M. Tavassoli, “Clinical Update on Cancer: Molecular Oncology of Head and Neck Cancer,” Cell Death & Disease5, no. 1 (January 2014): e1018.

[79] H. Yin, J. Qu, Q. Peng, and R. Gan, “Molecular Mechanisms of EBV-Driven Cell Cycle Progression and Oncogenesis,” Medical Microbiology and Immunology208, no. 5 (October 2019): 573–583.

[80] Y. Yoda, H. Takeshima, T. Niwa, et al., “Integrated Analysis of Cancer-Related Pathways Affected by Genetic and Epigenetic Alterations in Gastric Cancer,” Gastric Cancer18, no. 1 (January 2015): 65–76.

[81] M. A. Dawson and T. Kouzarides, “Cancer Epigenetics: From Mechanism to Therapy,” Cell150, no. 1 (July 2012): 12–27.

[82] V. Woo and T. Alenghat, “Epigenetic Regulation by Gut Microbiota,” Gut Microbes14, no. 1 (January–Dec 2022): 2022407.

[83] M. R. Rubinstein, X. Wang, W. Liu, Y. Hao, G. Cai, and Y. W. Han, “Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-cadherin/β-Catenin Signaling via Its FadA Adhesin,” Cell Host & Microbe14, no. 2 (August 2013): 195–206.

[84] N. Cullin, C. Azevedo Antunes, R. Straussman, C. K. Stein-Thoeringer, and E. Elinav, “Microbiome and Cancer,” Cancer Cell39, no. 10 (October 2021): 1317–1341.

[85] D. Hanahan and R. A. Weinberg, “Hallmarks of Cancer: The Next Generation,” Cell144, no. 5 (March 2011): 646–674.

[86] Y. W. Han, R. W. Redline, M. Li, L. Yin, G. B. Hill, and T. S. McCormick, “Fusobacterium nucleatum Induces Premature and Term Stillbirths in Pregnant Mice: Implication of Oral Bacteria in Preterm Birth,” Infection and Immunity72, no. 4 (April 2004): 2272–2279.

[87] J. Abed, J. E. Emgård, G. Zamir, et al., “Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc,” Cell Host & Microbe20, no. 2 (August 2016): 215–225.

[88] J. Sun, Q. Tang, S. Yu, et al., “F. nucleatum Facilitates Oral Squamous Cell Carcinoma Progression via GLUT1-Driven Lactate Production,” EBioMedicine88 (February 2023): 104444.

[89] S. Wu, Z. Ye, X. Liu, et al., “Salmonella typhimurium Infection Increases p53 Acetylation in Intestinal Epithelial Cells,” American Journal of Physiology-Gastrointestinal and Liver Physiology298, no. 5 (May 2010): G784–G794.

[90] R. Lu, M. Bosland, Y. Xia, Y. Zhang, I. Kato, and J. Sun, “Presence of Salmonella AvrA in Colorectal Tumor and Its Precursor Lesions in Mouse Intestine and Human Specimens,” Oncotarget8, no. 33 (August 2017): 55104–55115.

[91] T. Rossi, D. Vergara, F. Fanini, M. Maffia, S. Bravaccini, and F. Pirini, “Microbiota-Derived Metabolites in Tumor Progression and Metastasis,” International Journal of Molecular Sciences21, no. 16 (August 2020): 5786.

[92] D. Wirtz, K. Konstantopoulos, and P. C. Searson, “The Physics of Cancer: The Role of Physical Interactions and Mechanical Forces in Metastasis,” Nature Reviews Cancer11, no. 7 (June 2011): 512–522.

[93] T. N. Seyfried and L. C. Huysentruyt, “on the Origin of Cancer Metastasis,” Critical Reviews^TM in Oncogenesis18, no. 1–2 (2013): 43–73.

[94] X. Guan, “Cancer Metastases: Challenges and Opportunities,” Acta Pharmaceutica Sinica B5, no. 5 (September 2015): 402–418.

[95] M. Egeblad, M. G. Rasch, and V. M. Weaver, “Dynamic Interplay Between the Collagen Scaffold and Tumor Evolution,” Current Opinion in Cell Biology22, no. 5 (October 2010): 697–706.

[96] J. Massagué and A. C. Obenauf, “Metastatic Colonization by Circulating Tumour Cells,” Nature529, no. 7586 (January 2016): 298–306.

[97] A. Fu, B. Yao, T. Dong, and S. Cai, “Emerging Roles of Intratumor Microbiota in Cancer Metastasis,” Trends in Cell Biology33, no. 7 (July 2023): 583–593.

[98] C. W. Wong, A. Lee, L. Shientag, et al., “Apoptosis: An Early Event in Metastatic Inefficiency,” Cancer Research61, no. 1 (January 2001): 333–338.

[99] M. Shen and Y. Kang, “Stresses in the Metastatic Cascade: Molecular Mechanisms and Therapeutic Opportunities,” Genes & Development34, no. 23–24 (December 2020): 1577–1598.

[100] J. Liu, F. Luo, L. Wen, Z. Zhao, and H. Sun, “Current Understanding of Microbiomes in Cancer Metastasis,” Cancers15, no. 6 (March 2023): 1893.

[101] A. Bertocchi, S. Carloni, P. S. Ravenda, et al., “Gut Vascular Barrier Impairment Leads to Intestinal Bacteria Dissemination and Colorectal Cancer Metastasis to Liver,” Cancer Cell39, no. 5 (May 2021): 708–724.e11.

[102] Y. Murota and C. Jobin, “Bacteria Break Barrier to Promote Metastasis,” Cancer Cell39, no. 5 (May 2021): 598–600.

[103] S. Guo, J. Chen, F. Chen, Q. Zeng, W. L. Liu, and G. Zhang, “Exosomes Derived From Fusobacterium nucleatum-Infected Colorectal Cancer Cells Facilitate Tumour Metastasis by Selectively Carrying miR-1246/92b-3p/27a-3p and CXCL16,” Gut71, no. 2 (November 2020): e4.

[104] A. Hoshino, B. Costa-Silva, T. L. Shen, et al., “Tumour Exosome Integrins Determine Organotropic Metastasis,” Nature527, no. 7578 (November 2015): 329–335.

[105] M. Wu, G. Wang, W. Hu, Y. Yao, and X. F. Yu, “Emerging Roles and Therapeutic Value of Exosomes in Cancer Metastasis,” Molecular Cancer18, no. 1 (March 2019): 53.

[106] A. Fu, B. Yao, T. Dong, et al., “Tumor-Resident Intracellular Microbiota Promotes Metastatic Colonization in Breast Cancer,” Cell185, no. 8 (April 2022): 1356–1372.e26.

[107] Y. Wu, S. Guo, F. Chen, et al., “Fn-Dps, a Novel Virulence Factor of Fusobacterium nucleatum, Disrupts Erythrocytes and Promotes Metastasis in Colorectal Cancer,” PLoS Pathogens19, no. 1 (January 2023): e1011096.

[108] S. Parida, S. Wu, S. Siddharth, et al., “A Procarcinogenic Colon Microbe Promotes Breast Tumorigenesis and Metastatic Progression and Concomitantly Activates Notch and β-Catenin Axes,” Cancer Discovery11, no. 5 (May 2021): 1138–1157.

[109] H. Zhang, L. Fu, X. Leiliang, et al., “Beyond the Gut: The Intratumoral Microbiome's Influence on Tumorigenesis and Treatment Response,” Cancer Communications44, no. 10 (October 2024): 1130–1167.

[110] Z. Liu, X. Zhang, H. Zhang, et al., “Multi-Omics Analysis Reveals Intratumor Microbes as Immunomodulators in Colorectal Cancer,” Microbiology Spectrum11, no. 2 (February 2023): e0503822.

[111] K. D. LaCourse, M. Zepeda-Rivera, A. G. Kempchinsky, et al., “The Cancer Chemotherapeutic 5-Fluorouracil Is a Potent Fusobacterium nucleatum Inhibitor and Its Activity Is Modified by Intratumoral Microbiota,” Cell Reports41, no. 7 (November 2022): 111625.

[112] Y. Liu, Y. Baba, T. Ishimoto, et al., “Fusobacterium nucleatum Confers Chemoresistance by Modulating Autophagy in Oesophageal Squamous Cell Carcinoma,” British Journal of Cancer124, no. 5 (March 2021): 963–974.

[113] T. Yu, F. Guo, Y. Yu, et al., “Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy,” Cell170, no. 3 (July 2017): 548–563.

[114] A. Fulgione, F. Ianniello, M. Papaianni, et al., “Biomimetic Hydroxyapatite Nanocrystals Are an Active Carrier for Salmonella Bacteriophages,” International Journal of Nanomedicine14 (2019): 2219–2232.

[115] X. Zhang, X. Chen, Y. Guo, et al., “Dual Gate-Controlled Therapeutics for Overcoming Bacterium-Induced Drug Resistance and Potentiating Cancer Immunotherapy,” Angewandte Chemie International Edition60, no. 25 (June 2021): 14013–14021.

[116] D. Wei, Y. Sun, H. Zhu, and Q. Fu, “Stimuli-Responsive Polymer-Based Nanosystems for Cancer Theranostics,” ACS Nano17, no. 23 (December 2023): 23223–23261.

[117] Y. He, L. Lei, J. Cao, et al., “A Combinational Chemo-Immune Therapy Using an Enzyme-Sensitive Nanoplatform for Dual-Drug Delivery to Specific Sites by Cascade Targeting,” Science Advances7, no. 6 (February 2021): eaba0776.

[118] J. Chen, J. Ding, Y. Wang, et al., “Sequentially Responsive Shell-Stacked Nanoparticles for Deep Penetration into Solid Tumors,” Advanced Materials (Deerfield Beach, Fla)29, no. 32 (August 2017): 1701170.

[119] J. Cao, D. Huang, and N. A. Peppas, “Advanced Engineered Nanoparticulate Platforms to Address Key Biological Barriers for Delivering Chemotherapeutic Agents to Target Sites,” Advanced Drug Delivery Reviews167 (December 2020): 170–188.

[120] X. Liu, M. Sun, F. Pu, J. Ren, and X. Qu, “Transforming Intratumor Bacteria Into Immunopotentiators to Reverse Cold Tumors for Enhanced Immuno-Chemodynamic Therapy of Triple-Negative Breast Cancer,” Journal of the American Chemical Society145, no. 48 (December 2023): 26296–26307.

[121] M. Wang, B. Rousseau, K. Qiu, et al., “Killing Tumor-Associated Bacteria With a Liposomal Antibiotic Generates Neoantigens That Induce Anti-Tumor Immune Responses,” Nature Biotechnology42, no. 8 (August 2024): 1263–1274.

[122] T.-F. Ma, H.-X. Ma, C.-Y. Xing, et al., “Physiological and Proteomic Insights Into Silver Nanoparticle-Induced Stress Responses and Resistance Mechanisms in Aerobic Denitrifying Enterobacter Cloacae HNR,” Journal of Environmental Chemical Engineering13, no. 2 (2025): 115934.

[123] V. T. Noronha, J. C. Jackson, C. H. M. Camargos, A. J. Paula, C. A. Rezende, and A. F. Faria, “‘Attacking-Attacking’ Anti-Biofouling Strategy Enabled by Cellulose Nanocrystals-Silver Materials,” ACS Applied Bio Materials5, no. 3 (March 2022): 1025–1037.

[124] S. A. Dingsdag and N. Hunter, “Metronidazole: An Update on Metabolism, Structure-Cytotoxicity and Resistance Mechanisms,” Journal of Antimicrobial Chemotherapy73, no. 2 (February 2018): 265–279.

[125] X. Pan, P. Li, L. Bai, et al., “Biodegradable Nanocomposite With Dual Cell-Tissue Penetration for Deep Tumor Chemo-Phototherapy,” Small (Weinheim an der Bergstrasse, Germany)16, no. 22 (June 2020): e2000809.

[126] Y. Wang, Y. Han, C. Yang, et al., “Long-Term Relapse-Free Survival Enabled by Integrating Targeted Antibacteria in Antitumor Treatment,” Nature Communications15, no. 1 (May 2024): 4194.

[127] X. Qu, F. Yin, M. Pei, et al., “Modulation of Intratumoral Fusobacterium nucleatum to Enhance Sonodynamic Therapy for Colorectal Cancer With Reduced Phototoxic Skin Injury,” ACS Nano17, no. 12 (June 2023): 11466–11480.

[128] Y. Xin, Y. Yu, M. Wu, et al., “Tumor and Intratumoral Pathogen Cascade-Targeting Photothermal Nanotherapeutics for Boosted Immunotherapy of Colorectal Cancer,” Journal of Controlled Release379 (January 2025): 574–591.

[129] J. Wang, Y. Xin, D. Chen, et al., “Ultra-Stable Gold Nanoparticles With Tunable Surface Characteristics,” Angewandte Chemie (International ed. in English)64, no. 27 (July 2025): e202507954.

[130] W. Ban, M. Sun, H. Huang, et al., “Engineered Bacterial Outer Membrane Vesicles Encapsulating Oncolytic Adenoviruses Enhance the Efficacy of Cancer Virotherapy by Augmenting Tumor Cell Autophagy,” Nature Communications14, no. 1 (May 2023): 2933.

[131] L. Chen, Y. Shen, H. X. Shi, et al., “Engineered Bio-Heterojunction for Effective Treatment of Colorectal Cancer Through Intratumoral Bacteria Scavenging and Autophagy Regulation,” Advanced Functional Materials35, no. 22 (May 2025): 2421288.

[132] X. Li, Y. Ma, Y. Xin, F. Ma, and H. Gao, “Tumor-Targeting Nanoassembly for Enhanced Colorectal Cancer Therapy by Eliminating Intratumoral Fusobacterium nucleatum,” ACS Applied Materials & Interfaces15, no. 11 (March 2023): 14164–14172.

[133] R. Liu, H. Yang, S. Qu, et al., “Photodynamic Eradication of Intratumoral Microbiota With Bacteria-Targeted Micelles Overcomes Gemcitabine Resistance of Pancreatic Cancer,” Aggregate5, no. 1 (2024): e423.

[134] W. Wu, F. Guo, C. Wang, et al., “Biomimetic ‘Trojan Horse’ Nanoparticles With Biotactic Behavior Toward Tumor-Associated Bacteria for Targeted Therapy of Colorectal Cancer,” Cell Biomaterials1 (2025): 100092.

[135] I. Rady, I. A. Siddiqui, M. Rady, and H. Mukhtar, “Melittin, a Major Peptide Component of Bee Venom, and Its Conjugates in Cancer Therapy,” Cancer Letters402 (August 2017): 16–31.

[136] R. Roudi, N. L. Syn, and M. Roudbary, “Antimicrobial Peptides As Biologic and Immunotherapeutic Agents Against Cancer: A Comprehensive Overview,” Frontiers in Immunology8 (2017): 1320.

[137] Y. Xie, J. Wang, L. Li, et al., “A Metal Chelation Therapy to Effectively Eliminate Breast Cancer and Intratumor Bacteria While Suppressing Tumor Metastasis by Copper Depletion and Zinc Ions Surge,” Angewandte Chemie (International ed. in English)64, no. 5 (January 2025): e202417592.

[138] X. Wang, Q. Chen, Y. Zhu, et al., “Destroying Pathogen-Tumor Symbionts Synergizing With Catalytic Therapy of Colorectal Cancer by Biomimetic Protein-Supported Single-Atom Nanozyme,” Signal Transduction and Targeted Therapy8, no. 1 (July 2023): 277.

[139] Q. Chen, Y. F. Zhu, K. R. Wang, et al., “Clearing Intratumoral Bacteria to Augment Tumor-Therapeutic Response by Engineering Antimicrobial Dendritic Mesoporous Silica Nanomedicine,” Nano Today52 (October 2023): 101994.

[140] M. L. Wang, B. Rousseau, K. Y. Qiu, et al., “Killing Tumor-Associated Bacteria With a Liposomal Antibiotic Generates Neoantigens That Induce Anti-Tumor Immune Responses,” Nature Biotechnology42, no. 8 (August 2024): 1263–1274.

[141] Z. Y. Han, Q. W. Chen, D. W. Zheng, et al., “Inhalable Capsular Polysaccharide-Camouflaged Gallium-Polyphenol Nanoparticles Enhance Lung Cancer Chemotherapy by Depleting Local Lung Microbiota,” Advanced Materials (Deerfield Beach, Fla)35, no. 38 (September 2023): 2302551.

[142] L. Chen, Z. Kang, J. Shen, et al., “An Emerging Antibacterial Nanovaccine for Enhanced Chemotherapy by Selectively Eliminating Tumor-Colonizing Bacteria,” Science Bulletin69, no. 16 (August 2024): 2565–2579.

[143] X. Kang, F. Bu, W. Feng, et al., “Dual-Cascade Responsive Nanoparticles Enhance Pancreatic Cancer Therapy by Eliminating Tumor-Resident Intracellular Bacteria,” Advanced Materials (Deerfield Beach, Fla)34, no. 49 (December 2022): e2206765.

[144] H. Jiang, Y. Guo, Z. Yu, P. Hu, and J. Shi, “Nanocatalytic Bacteria Disintegration Reverses Immunosuppression of Colorectal Cancer,” National Science Review9, no. 11 (November 2022): 169.

[145] J. Liu, W. Bu, and J. Shi, “Chemical Design and Synthesis of Functionalized Probes for Imaging and Treating Tumor Hypoxia,” Chemical Reviews117, no. 9 (May 2017): 6160–6224.

[146] D. C. Singleton, A. Macann, and W. R. Wilson, “Therapeutic Targeting of the Hypoxic Tumour Microenvironment,” Nature Reviews Clinical Oncology18, no. 12 (December 2021): 751–772.

[147] H. Kim, J. Yoon, H. K. Kim, et al., “Upconverting Nanoparticle-Containing Erythrocyte-Sized Hemoglobin Microgels That Generate Heat, Oxygen and Reactive Oxygen Species for Suppressing Hypoxic Tumors,” Bioactive Materials22 (April 2023): 112–126.

[148] J. Zou, C. Jiang, Q. Hu, et al., “Tumor Microenvironment-Responsive Engineered Hybrid Nanomedicine for Photodynamic-Immunotherapy via Multi-Pronged Amplification of Reactive Oxygen Species,” Nature Communications16, no. 1 (January 2025): 424.

[149] L. Zhang, X. Du, Q. Li, et al., “A Multimodal Therapeutic Nanoplatform Overcoming Tumor Hypoxia Heterogeneity for Improved Tumor Chemoradiotherapy,” Advanced Functional Materials32, no. 34 (2022): 2204629.

[150] F. Yang, S. Li, Q. Ji, et al., “Modular Prodrug-Engineered Oxygen Nano-Tank With Outstanding Nanoassembly Performance, High Oxygen Loading, and Closed-Loop Tumor Hypoxia Relief,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany)11, no. 34 (September 2024): e2405583.

[151] M. Gao, C. Liang, X. Song, et al., “Erythrocyte-Membrane-Enveloped Perfluorocarbon as Nanoscale Artificial Red Blood Cells to Relieve Tumor Hypoxia and Enhance Cancer Radiotherapy,” Advanced Materials29, no. 35 (September 2017): 1701429.

[152] E. Jung, S. Kwon, N. Song, et al., “Tumor-Targeted Redox-Regulating and Antiangiogenic Phototherapeutics Nanoassemblies for Self-Boosting Phototherapy,” Biomaterials298 (July 2023): 122127.

[153] Y. Deng, Z. Jiang, Y. Jin, et al., “Reinforcing Vascular Normalization Therapy With a Bi-Directional Nano-System to Achieve Therapeutic-Friendly Tumor Microenvironment,” Journal of Controlled Release340 (December 2021): 87–101.

[154] S. Y. Wang, M. M. Cheng, S. H. Wang, et al., “A Self-Catalytic NO/O₂ Gas-Releasing Nanozyme for Radiotherapy Sensitization Through Vascular Normalization and Hypoxia Relief,” Advanced Materials (Deerfield Beach, Fla)36, no. 39 (September 2024): e2403921.

[155] M. Chang, Z. Wang, C. Dong, et al., “Ultrasound-Amplified Enzyodynamic Tumor Therapy by Perovskite Nanoenzyme-Enabled Cell Pyroptosis and Cascade Catalysis,” Advanced Materials (Deerfield Beach, Fla)35, no. 7 (February 2023): e2208817.

[156] Y. Y. Liu, L. H. Xiang, Y. T. Li, et al., “Bacteria-Mediated Tumor-Targeting Delivery of Multienzyme-Mimicking Covalent Organic Frameworks Promoting Pyroptosis for Combinatorial Sono-Catalytic Immunotherapy,” Advancement of Science11, no. 47 (December 2024): e2407133.

[157] L. Gao and X. Yan, “Nanozymes: An Emerging Field Bridging Nanotechnology and Biology,” Science China Life Sciences59, no. 4 (April 2016): 400–402.

[158] J. M. M. Levy, C. G. Towers, and A. Thorburn, “Targeting Autophagy in Cancer,” Nature Reviews Cancer17, no. 9 (September 2017): 528–542.

[159] G. Filomeni, D. De Zio, and F. Cecconi, “Oxidative Stress and Autophagy: The Clash Between Damage and Metabolic Needs,” Cell Death & Differentiation22, no. 3 (March 2015): 377–388.

[160] S. Yan, N. Zhou, D. Zhang, et al., “PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances Its Cytotoxicity in Colon Cancer Cells,” International Journal of Molecular Sciences20, no. 21 (October 2019): 5415.

[161] G. Liu, X. Fan, M. Tang, et al., “Osteopontin Induces Autophagy to Promote Chemo-Resistance in Human Hepatocellular Carcinoma Cells,” Cancer Letters383, no. 2 (December 2016): 171–182.

[162] M. M. Sun, L. L. Wang, Y. Zhuo, et al., “Multi-Enzyme Activity of MIL-101 (Fe)-Derived Cascade Nano-Enzymes for Antitumor and Antimicrobial Therapy,” Small (Weinheim an der Bergstrasse, Germany)20, no. 17 (April 2024): e2309593.

[163] Y. J. Zhang, J. J. Zhao, L. M. Zhang, et al., “A Cascade Nanoreactor for Enhancing Sonodynamic Therapy on Colorectal Cancer via Synergistic Ros Augment and Autophagy Blockage,” Nano Today49 (April 2023): 101798.

[164] D. V. Krysko, A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, and P. Vandenabeele, “Immunogenic Cell Death and DAMPs in Cancer Therapy,” Nature Reviews Cancer12, no. 12 (December 2012): 860–875.

[165] O. Kepp, L. Senovilla, I. Vitale, et al., “Consensus Guidelines for the Detection of Immunogenic Cell Death,” Oncoimmunology3, no. 9 (October 2014): e955691.

[166] B. Wu, J. Fu, Y. Zhou, et al., “Tailored Core–Shell Dual Metal-Organic Frameworks as a Versatile Nanomotor for Effective Synergistic Antitumor Therapy,” Acta Pharmaceutica Sinica B10, no. 11 (November 2020): 2198–2211.

[167] V. Gopalakrishnan, B. A. Helmink, C. N. Spencer, A. Reuben, and J. A. Wargo, “The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy,” Cancer Cell33, no. 4 (April 2018): 570–580.

[168] L. Qu, G. Cui, Y. Sun, et al., “A Biomimetic Autophagosomes-Based Nanovaccine Boosts Anticancer Immunity,” Advanced Materials (Deerfield Beach, Fla)36, no. 40 (October 2024): e2409590.

[169] S. Qi, X. Zhang, X. Yu, et al., “Supramolecular Lipid Nanoparticles Based on Host-Guest Recognition: A New Generation Delivery System of mRNA Vaccines For Cancer Immunotherapy,” Advanced Materials (Deerfield Beach, Fla)36, no. 23 (June 2024): e2311574.

[170] X. Ding, J. Zhang, S. Wan, et al., “Non-Discriminating Engineered Masking of Immuno-Evasive Ligands on Tumour-Derived Extracellular Vesicles Enhances Tumour Vaccination Outcomes,” Nature Nanotechnology20, no. 1 (January 2025): 156–166.

[171] H. Chen, Z. Zhu, K. Lv, et al., “Uniform Polymeric Nanovaccine Platform for Improving the Availability and Efficacy of Neoantigen Peptides,” Nano Letters24, no. 33 (August 2024): 10114–10123.

[172] J. Li, D. Huang, R. Cheng, et al., “Multifunctional Biomimetic Nanovaccines Based on Photothermal and Weak-Immunostimulatory Nanoparticulate Cores for the Immunotherapy of Solid Tumors,” Advanced Materials (Deerfield Beach, Fla)34, no. 9 (March 2022): e2108012.

[173] T. Li, G. Chen, L. Lin, et al., “Manganese Oxide-Constructed Multifunctional Biomimetic Nanovaccine for Robust Tumor-Specific T Cell Priming and Chemodynamic Therapy,” Biomaterials309 (September 2024): 122626.

[174] Y. Lv, F. Li, S. Wang, et al., “Near-Infrared Light-Triggered Platelet Arsenal for Combined Photothermal-Immunotherapy Against Cancer,” Science Advances7, no. 13 (March 2021): eabd7614.

[175] S. Pushalkar, M. Hundeyin, D. Daley, et al., “The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression,” Cancer Discovery8, no. 4 (April 2018): 403–416.

[176] A. Mantovani, F. Marchesi, A. Malesci, L. Laghi, and P. Allavena, “Tumour-Associated Macrophages as Treatment Targets in Oncology,” Nature Reviews Clinical Oncology14, no. 7 (July 2017): 399–416.

[177] A. Sica, P. Larghi, A. Mancino, et al., “Macrophage Polarization in Tumour Progression,” Seminars in Cancer Biology18, no. 5 (October 2008): 349–355.

[178] Y. Gong, W. Gao, J. Zhang, X. Dong, D. Zhu, and G. Ma, “Engineering Nanoparticles-Enabled Tumor-Associated Macrophages Repolarization and Phagocytosis Restoration for Enhanced Cancer Immunotherapy,” Journal of Nanobiotechnology22, no. 1 (June 2024): 341.

[179] J. Qin, J. Liu, Z. Wei, et al., “Targeted Intervention in Nerve-Cancer Crosstalk Enhances Pancreatic Cancer Chemotherapy,” Nature Nanotechnology20, no. 2 (February 2025): 311–324.

[180] Z. Huang, Z. Zhang, Y. Jiang, et al., “Targeted Delivery of Oligonucleotides Into Tumor-Associated Macrophages for Cancer Immunotherapy,” Journal of Controlled Release158, no. 2 (March 2012): 286–292.

[181] Z. Y. Han, Z. J. Fu, Y. Z. Wang, et al., “Probiotics Functionalized With a Gallium-Polyphenol Network Modulate the Intratumor Microbiota and Promote Anti-Tumor Immune Responses in Pancreatic Cancer,” Nature Communications15, no. 1 (August 2024): 7096.

[182] X. Li, M. Wu, Y. Wu, et al., “Multifunctional Nanodrug for Simultaneously Combating Chemoresistance and Immunosuppression in Fusobacterium nucleatum-Associated Colorectal Cancer,” Acta Biomaterialia195 (February 2025): 406–420.

[183] K. Li, J. Wang, Y. Xie, et al., “Reactive Oxygen Species/Glutathione Dual Sensitive Nanoparticles With Encapsulation of miR155 and Curcumin for Synergized Cancer Immunotherapy,” Journal of Nanobiotechnology22, no. 1 (July 2024): 400.

[184] A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica, “Macrophage Polarization: Tumor-Associated Macrophages as a Paradigm for Polarized M2 Mononuclear Phagocytes,” Trends in Immunology23, no. 11 (November 2002): 549–555.

[185] H. Zhang, L. Liu, J. Liu, et al., “Roles of Tumor-Associated Macrophages in Anti-PD-1/PD-L1 Immunotherapy for Solid Cancers,” Molecular Cancer22, no. 1 (March 2023): 58.

[186] X. Bi, J. Wang, and C. Liu, “Intratumoral Microbiota: Metabolic Influences and Biomarker Potential in Gastrointestinal Cancer,” Biomolecules14, no. 8 (July 2024): 917.

[187] L. E. Colbert, M. B. El Alam, R. Wang, et al., “Tumor-Resident Lactobacillus iners Confer Chemoradiation Resistance Through Lactate-Induced Metabolic Rewiring,” Cancer Cell41, no. 11 (November 2023): 1945–1962.e11.

[188] L. T. Geller, M. Barzily-Rokni, T. Danino, et al., “Potential Role of Intratumor Bacteria in Mediating Tumor Resistance to the Chemotherapeutic Drug Gemcitabine,” Science (New York, NY)357, no. 6356 (September 2017): 1156–1160.

[189] K. Huang, J. B. Wang, Q. H. Zhang, et al., “Sub 150 nm Nanoscale Gallium Based Metal-Organic Frameworks Armored Antibiotics as Super Penetrating Bombs for Eradicating Persistent Bacteria,” Advanced Functional Materials32, no. 43 (October 2022): 2204906.

[190] X. L. Hong, T. C. Yu, X. W. Huang, et al., “Metformin Abrogates Fusobacterium nucleatum-Induced Chemoresistance in Colorectal Cancer by Inhibiting miR-361-5p/Sonic Hedgehog Signaling-Regulated Stemness,” British Journal of Cancer128, no. 2 (January 2023): 363–374.

[191] H. Dong, J. Huang, K. Zheng, et al., “Metformin Enhances the Chemosensitivity of Hepatocarcinoma Cells to Cisplatin Through AMPK Pathway,” Oncology Letters14, no. 6 (December 2017): 7807–7812.

[192] K. L. Yip, T. N. Tsai, I. P. Yang, et al., “Metformin Enhancement of Therapeutic Effects of 5-Fluorouracil and Oxaliplatin in Colon Cancer Cells and Nude Mice,” Biomedicines10, no. 5 (April 2022): 955.

[193] X. Wu, C. He, Y. Wu, and X. Chen, “Synergistic Therapeutic Effects of Schiff's Base Cross-Linked Injectable Hydrogels for Local Co-Delivery of Metformin and 5-Fluorouracil in a Mouse Colon Carcinoma Model,” Biomaterials75 (January 2016): 148–162.

[194] I. Manoharan, P. D. Prasad, M. Thangaraju, and S. Manicassamy, “Lactate-Dependent Regulation of Immune Responses by Dendritic Cells and Macrophages,” Frontiers in Immunology12 (2021): 691134.

[195] H. Lemos, L. Huang, G. C. Prendergast, and A. L. Mellor, “Immune Control by Amino Acid Catabolism During Tumorigenesis and Therapy,” Nature Reviews Cancer19, no. 3 (March 2019): 162–175.

[196] B. Allard, P. A. Beavis, P. K. Darcy, and J. Stagg, “Immunosuppressive Activities of Adenosine in Cancer,” Current Opinion in Pharmacology29 (August 2016): 7–16.

[197] M. H. Oh, I. H. Sun, L. Zhao, et al., “Targeting Glutamine Metabolism Enhances Tumor-Specific Immunity by Modulating Suppressive Myeloid Cells,” Journal of Clinical Investigation130, no. 7 (July 2020): 3865–3884.

[198] J. Cong, P. Liu, Z. Han, et al., “Bile Acids Modified by the Intestinal Microbiota Promote Colorectal Cancer Growth by Suppressing CD8(+) T Cell Effector Functions,” Immunity57, no. 4 (April 2024): 876–889.e11.

[199] M. G. Vander Heiden, L. C. Cantley, and C. B. Thompson, “Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation,” Science324, no. 5930 (May 2009): 1029–1033.

[200] K. C. Kao, S. Vilbois, C. H. Tsai, and P. C. Ho, “Metabolic Communication in the Tumour-Immune Microenvironment,” Nature Cell Biology24, no. 11 (November 2022): 1574–1583.

[201] Z. Y. Han, C. Zhang, J. X. An, et al., “Metabolic Regulation of Tumor Microenvironment With Biohybrid Bacterial Bioreactor for Enhanced Cancer Chemo-Immunotherapy,” Advanced Functional Materials33, no. 35 (August 2023): 2302728.

[202] S. M. Zhang, X. K. Jin, G. F. Luo, et al., “An Engineered Bacterium-Based Lactate Bioconsumer for Regulating Immunosuppressive Tumor Microenvironment to Potentiate Antitumor Immunity,” ACS Materials Letters5, no. 10 (September 2023): 2785–2798.

[203] M. Certo, C. H. Tsai, V. Pucino, P. C. Ho, and C. Mauro, “Lactate Modulation of Immune Responses in Inflammatory Versus Tumour Microenvironments,” Nature Reviews Immunology21, no. 3 (March 2021): 151–161.

[204] Z. Zong, F. Xie, S. Wang, et al., “Alanyl-tRNA Synthetase, AARS1, Is a Lactate Sensor and Lactyltransferase That Lactylates p53 and Contributes to Tumorigenesis,” Cell187, no. 10 (May 2024): 2375–2392.e33.

[205] L. Ippolito, A. Morandi, E. Giannoni, and P. Chiarugi, “Lactate: A Metabolic Driver in the Tumour Landscape,” Trends in Biochemical Sciences44, no. 2 (February 2019): 153–166.

[206] C. T. Inglut, A. J. Sorrin, T. Kuruppu, et al., “Immunological and Toxicological Considerations for the Design of Liposomes,” Nanomaterials10, no. 2 (January 2020): 190.

[207] J. Y. Zhou, Q. H. Shen, Y. W. Xiong, et al., “Zinc-Mediated Metalloimmunotherapy With Dual Elimination of Tumor and Intratumoral Bacteria in Oral Squamous Cell Carcinoma,” Biomaterials323 (December 2025): 123439.

[208] Q. Zhang, S. Yan, X. Yan, and Y. Lv, “Recent Advances in Metal-Organic Frameworks: Synthesis, Application and Toxicity,” Science of the Total Environment902 (December 2023): 165944.

[209] W. S. Liu, L. L. Wu, C. M. Chen, et al., “Lipid-Hybrid Cell-Derived Biomimetic Functional Materials: A State-of-the-Art Multifunctional Weapon Against Tumors,” Materials Today Bio22 (October 2023): 100751.

[210] Y. Gong and J. Huang, “Application of Biomimetic Nanoparticles Based on the Cell Membrane in Tumor Therapy,” Current Topics in Medicinal Chemistry23, no. 10 (2023): 907–920.

[211] X. Zhang, X. Chen, and Y. Zhao, “Nanozymes: Versatile Platforms for Cancer Diagnosis and Therapy,” Nano-Micro Letters14, no. 1 (April 2022): 95.

[212] N. Chakraborty, S. Gandhi, R. Verma, and I. Roy, “Emerging Prospects of Nanozymes for Antibacterial and Anticancer Applications,” Biomedicines10, no. 6 (June 2022): 1378.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Biomaterials and Applications published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).